Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31709039 | 0.93 | CHRM3 (0.41) | CHRM3OPRM1BCHEACHECACNA1F | |
| SCHEMBL31709053 | 0.93 | ALDH1A1 (0.40) | ALDH1A1KDM4EALOX15TDP1BCHE | |
| SCHEMBL31709208 | 0.93 | SIGMAR1 (0.42) | ALDH1A1KDM4EALOX15 | |
| SCHEMBL31709007 | 0.93 | HTR2A (0.43) | ALDH1A1KDM4ECHRM3OPRM1 | |
| SCHEMBL31708964 | 0.92 | CHRM3 (0.41) | ALDH1A1KDM4ECHRM3ALOX15TDP1 | |
| SCHEMBL31709300 | 0.92 | CHRM3 (0.42) | ALDH1A1KDM4ECHRM3OPRM1 | |
| SCHEMBL31709217 | 0.92 | KDM4E (0.39) | ALDH1A1KDM4EOPRM1ALOX15TDP1 | |
| SCHEMBL31708941 | 0.92 | ALDH1A1 (0.39) | ALDH1A1KDM4EOPRM1ALOX15TDP1 | |
| SCHEMBL31709332 | 0.91 | CHRM3 (0.43) | ALDH1A1KDM4ECHRM3ALOX15TDP1 | |
| SCHEMBL31708760 | 0.91 | KDM4E (0.38) | ALDH1A1KDM4EOPRM1ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | ALDH1A1 774/4885KDM4E 2774/4885CHRM3 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.